Days
Hours
Minutes
Ocular melanoma survivor Anne Marie Montijo reflects on the passing of Dr. Oliver Sacks and her own goal to live each day with a spirit of gratitude.
Today, the FDA approved the targeted therapy combination of vemurafenib (Zelboraf®) with cobimetinib (Cotellic) for people who have advanced or metastatic melanoma and who...
Washington, D.C. – On Saturday, November 7th, the Washington, D.C. melanoma community will come together to honor those who have been impacted by melanoma and raise f...
The results are in and #CUREOM Unite! was a tremendous success! Thank you to everyone who gave so generously to this campaign to further patient-centered ocular melanoma (O...
Statement from Tim Turnham, Executive Director, Melanoma Research Foundation Washington, D.C.—Today the Food and Drug Administration (FDA) approved ipilimumab ...
Today the FDA approved Amgen’s drug, Imlygic (Talimogene Laherparepvec or T-VEC), for the treatment of unresectable Stage IIIB, IIIC or IV metastatic melanoma, bringing a...
For the last decade, Dr. Richard Carvajal has dedicated his career to the research and treatment of rare cancers like ocular melanoma (OM) and understands the need for more...
Guest blogger Connie Popp shares her experience as an ocular melanoma caregiver, advocate and participant in Miles for Melanoma in support of the CURE OM Unite! campaign. 3 Minute Read
Statement from Tim Turnham, Executive Director, Melanoma Research Foundation The Melanoma Research Foundation (MRF) applauds the FDA’s approval of the c...
Leanda Cave Partners with the Melanoma Research Foundation to Raise Awareness of the Deadliest Form of Skin Cancer WASHINGTON, D.C.— Four-time Triathlon World ...
The Melanoma Research Foundation submitted a letter to the Office of Management and Budget (OMB) urging it to take the critical step toward reducing skin cancers. The Food ...
Guest blogger Frank Nichols shares his story as an ocular melanoma patient, advocate and participant in Miles for Melanoma NYC.
Dec 02, 2025 ET
Dec 13, 2025 CT
